The FDA has signed off in Moderna’s (MRNA -2.3%) IND for mRNA-1273, its vaccine candidate against SARS-CoV-2, the coronavirus causing the current outbreak.
The first batch of product has been shipped to and received by the NIH for use in a Phase 1 study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.